INNATE PHARMA

IPH
Real-time Quote. Real-time  - 11/29 11:35:12 am
4.498EUR +4.75%
Business Summary
Healthcare
Pharmaceuticals & Medical Research
 Biotechnology & Medical Research
  Biotechnology & Medical Research
   Other Biotechnology & Medical Research
Innate Pharma SA is a France-based biopharmaceutical Company that develops drugs for treatment of cancer and inflammatory diseases. The Company identifies and characterizes drug candidates, selects indications and manages the pre-clinical and clinical development of products. Innate Pharma primarily focuses on the development of new therapeutic solutions and monoclonal antibodies for the treatment of cancer, as well as for the treatment of infectious diseases and chronic inflammatory pathologies. The Company develops two categories of immunotherapies: immuno-modulators and cytotoxic antibodies. The Company works in collaboration with Bristol-Myers Squibb for Phase I cancer antibody program and with Novo Nordisk A/S for two antibody programs in inflammation treatment. The Company operates through anti-NKG2A antibody, an immune checkpoint inhibitor ready for Phase II development in oncology from Novo Nordisk.

Number of employees : 237 people.
Sales per Business
20192020
Therapeutic Antibodies85.81124.4%70.45124%
EUR in Million
Sales per region
20192020
France85.81124.4%70.45124%
EUR in Million
Managers
Name Title
Mondher Mahjoubi Chairman-Executive Board & Chief Executive Officer
Frederic Lombard Chief Financial Officer
Hervé Eloi Dominique Brailly Chairman-Supervisory Board
Eric Vivier Chief Scientific Officer & Senior Vice President
Odile Belzunce Senior VP-Compliance, IT & Operations
Joyson Joseph Karakunnel Chief Medical Officer & Executive Vice President
Patrick J. Langlois Independent Member-Supervisory Board
Irina Staatz-Granzer Vice Chairman-Supervisory Board
Véronique Chabernaud Independent Member-Supervisory Board
Jean-Yves Blay Independent Member-Supervisory Board
Shareholders
Name Equities %
Novo Nordisk A/S 9,817,546 12.4%
Bpifrance Participations SA /PRIVATE EQUITY/ 8,952,467 11.3%
AstraZeneca PLC 7,485,500 9.48%
Hervé Eloi Dominique Brailly 885,884 1.12%
BlackRock Fund Advisors 365,055 0.46%
Baillie Gifford & Co. 355,227 0.45%
Sycomore Asset Management SA 349,573 0.44%
Saint Olive Gestion SNC 345,000 0.44%
Mondher Mahjoubi 342,511 0.43%
HSBC Global Asset Management (France) SA 312,730 0.40%
Company contact information
117 Avenue de Luminy
BP 30191
FR-13009 Marseille


Phone : +33 (0)4 30 30 30 30
Fax : +33 (0)4 30 30 30 00
web site : http://www.innate-pharma.com
Markets and indexes
- Compartiment B
- Next 150 / CAC All Shares, CAC All-Tradable, CAC Mid Small, CAC PME, CAC Small, EnterNext© PEA-PME 150, Next Biotech, PEA, PEA-PME, Tech 40
Stock Exchange Codes
- Bloomberg Code :  IPH:FP
- Reuters Code :  IPH.PA
Sector Other Biotechnology & Medical Research
1st jan.Capi. (M$)
INNATE PHARMA S.A.22.00%384
MODERNA, INC.252.74%133 648
LONZA GROUP AG28.41%59 443
IQVIA HOLDINGS INC.48.85%50 064
SEAGEN INC.-5.61%30 994
CELLTRION, INC.-40.81%24 431
ALNYLAM PHARMACEUTICALS, INC.39.06%22 548
PHARMARON BEIJING CO., LTD.54.31%22 426
ICON PUBLIC LIMITED COMPANY41.59%22 140
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.50.20%18 938
BIO-TECHNE CORPORATION51.06%18 605
HANGZHOU TIGERMED CONSULTING CO., LTD-13.90%18 314
PPD, INC.38.37%16 639
NOVAVAX, INC.73.94%16 480
INCYTE CORPORATION-19.10%15 105
QIAGEN N.V.5.24%12 820
PRA HEALTH SCIENCES, INC.0.00%10 965
BACHEM HOLDING AG73.70%10 880
GENSCRIPT BIOTECH CORPORATION259.04%10 799
SYNEOS HEALTH, INC.45.02%10 245
UNITED THERAPEUTICS CORPORATION27.81%8 721
Brand Portfolio
INNATE PHARMA
INNATE PHARMA
» More brands of Innate Pharma